Prevalence of HIV and hepatitis B coinfection in Ghana: a systematic review and meta-analysis by unknown
Agyeman and Ofori‑Asenso  AIDS Res Ther  (2016) 13:23 
DOI 10.1186/s12981‑016‑0107‑x
REVIEW
Prevalence of HIV and hepatitis B 
coinfection in Ghana: a systematic review 
and meta‑analysis
Akosua Adom Agyeman and Richard Ofori‑Asenso*
Abstract 
Background: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection has been associated with 
higher morbidity and mortality and may impact significantly on healthcare resource utilization. However, in Ghana, 
accurate estimates of the prevalence of HIV/HBV coinfection needed to inform policy decisions and the design of 
public health interventions are currently lacking. In this study, our aim was to determine the HIV/HBV coinfection 
prevalence rate in Ghana.
Methods: Primary studies reporting prevalence of HIV/HBV coinfection in Ghana were retrieved through searches 
conducted in PubMed, science direct, Google scholar and Africa journals online (AJOL) databases. The websites of the 
Ministry of Health and Ghana Health Service were also searched for related reports or reviews. Additionally, the online 
repository of two leading Ghanaian universities were searched to identify unpublished thesis related to the subject. 
All online searches were conducted between 01/03/2016 and 12/03/2016. Further searches were conducted through 
reference screening of retrieved papers.
Results: Twelve (12) studies published between 1999 and 2016 and conducted across seven (7) regions of Ghana 
were included in this review. The three (3) regions with no studies’ representation were Upper East, Upper West and 
Central regions. The 12 included studies involved a total of 8162 HIV patients. The reported HIV/HBV coinfection 
prevalence rates ranged from 2.4 to 41.7 %. The pooled HIV/HBV coinfection prevalence rate was determined as 
13.6 % (95 % CI 10.2–16.8 %; P < 0.001).
Conclusions: In Ghana, about one in seven HIV patients may be also be chronically infected with HBV. Preventive 
interventions and strategic policy directions including systematic screening of all newly diagnosed HIV cases for 
coinfection will be needed, so as to improve management strategies for HBV infection and antiretroviral therapy (ART) 
implementation.
Keywords: HIV, Hepatitis B, Coinfection, Prevalence, Ghana, Meta‑analysis
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human immunodeficiency virus (HIV) and hepatitis B 
virus (HBV) coinfection is common due to their shared 
transmission routes [1, 2]. Approximately, 10  % of all 
HIV infected patients worldwide are estimated to have 
chronic HBV coinfection [3]. However, wide regional 
variations are observed with coinfection prevalence rates 
estimated to be 5–10 % in areas such as North America, 
Europe and Australia compared to higher prevalence 
rates of 20–30 % in areas such as Sub-Saharan Africa and 
Asia [1, 2]. These statistics are of significant importance 
in Sub-Saharan Africa where over 70 % of the world’s 36.9 
million people infected with HIV live [4].
Although, the specific mechanisms by which HBV 
interacts with HIV to influence disease progression are 
not clearly understood, HIV/HBV coinfection has been 
identified to facilitate higher levels of HBV replication, 
decreased rates of spontaneous resolution of the HBV 
infection, and higher risk of reactivation of previous 
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infections [5–7]. Subsequently, HIV infected individuals 
have been found to be about six (6) times more likely to 
develop chronic HBV infection than their HIV negative 
counterparts [1, 8]. Additionally, the progression rate and 
complications such as liver fibrosis, cirrhosis, end-stage 
liver disease, hepatocellular carcinoma (HCC) and mor-
tality due to liver pathology arising from HBV infection 
are accelerated in patients with HIV coinfection [3, 7]. In 
a recent synthesis of data from 12,382 patients in Greece 
for instance, there was a demonstrable significant 36  % 
increased rate of mortality attributable to the effect of 
HBV coinfection in HIV patients [9].
Antiretroviral therapy (ART) can be very challeng-
ing when coinfection is present as HIV-infected indi-
viduals are usually less responsive to treatments for HBV 
and have raised risk of hepatotoxicity and drug interac-
tions [10, 11]. However, medications active against both 
HIV and HBV may allow for simplification of treatment 
regimen, although the overlapping antiviral spectrum 
of some HIV and HBV therapies can lead to additional 
complexities as a result of increased potential for the 
selection of drug-resistant mutations [10, 12].
In light of these background information, accurate 
estimates of the prevalence of HIV/HBV coinfection 
will be essential to inform evidence-based policy mak-
ing (e.g. scaling up of screening programs) and resource 
allocation as well as impact positively on general preven-
tion and treatment strategies for HBV/HIV coinfection 
especially regarding the use of highly active antiretrovi-
ral therapy (HAART) agents that also possess anti-HBV 
activity and its attendant implications [10].
A systematic review conducted by Barth et al. in 2010, 
estimated the overall prevalence of HIV/HBV coinfection 
in Sub Saharan Africa to be 15 % [13]. While this may be 
informative, it may not entirely represent the situation in 
Ghana as participants from studies conducted in Nige-
ria contributed more than two-fifth (40 %) of the overall 
population in that review [13]. Country-specific infor-
mation regarding HIV/HBV coinfection prevalence that 
is relevant, defined and up to date may therefore serve 
greater purpose at informing specific prevention and 
treatment policies within Ghana. However, we have not 
found any published systematic review and meta-analy-
sis specifically summarizing the prevalence of HIV/HBV 
coinfection in Ghana. We consider this to constitute an 
insufficient documentation of the country’s burden of 
HIV/HBV coinfection.
This study was therefore conducted to summarize the 
available information towards answering the key ques-
tion; what is the prevalence of HIV/HBV coinfection in 
Ghana? This work was carried out as part of our series 
of research documenting the burden of viral hepatitis in 
Ghana.
Methods
This review was conducted in accordance with the 
PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) guidelines [14].
Search strategy
To identify relevant studies, comprehensive searches were 
conducted by RO in PubMed, Science direct, Google 
SCHOLAR, and Africa journals online (AJOL) databases. 
The key words used were Hepatitis B, Hepatitis B surface 
antigen (HBsAg), HBV, HBV-DNA, human immunode-
ficiency virus, HIV, AIDS, coinfection, Prevalence and 
Ghana. In many instances, a combination of these keywords 
were explored (See "Appendix" section). AA also searched 
the digital institutional repository of the two leading Gha-
naian universities, University of Ghana Legon (http://www.
ugspace.ug.edu.gh/) and Kwame Nkrumah University of 
Science and Technology (http://www.ir.knust.edu.gh/) to 
identify unpublished thesis related to the subject. The web-
sites of the Ministry of Health (http://www.moh-ghana.
org/) and the Ghana Health Service (http://www.ghana-
healthservice.org/) were also searched for related reports 
and reviews using selected phrases such as ‘Hepatitis B and 
HIV coinfection’. Online searches were conducted between 
01/03/2016 and 12/03/2016. All references in selected arti-
cles were further screened for additional publications.
Inclusion and exclusion of studies
Studies were included only if they reported chronic HBV 
infection prevalence rate among HIV-infected persons in 
Ghana. As generally recommended, laboratory diagnosis of 
chronic HBV infection focuses on the detection of hepatitis 
B surface antigen (HBsAg) [15]. Hence, only studies report-
ing prevalence of HBV in HIV persons based on HBsAg 
seropositivity were included. Studies reporting HBV prev-
alence in general populations (HIV negative cohorts) or 
those presenting HIV/hepatitis C (HCV) coinfection prev-
alence were excluded. Only studies published in English 
were selected. For duplicate studies, the version published 
first or one with complete dataset were included.
Quality assessment and data extraction
Studies’ qualities were assessed using a 12-point scor-
ing system based on the Downs and Black checklist 
as adopted in similar reviews [10, 16, 17]. These were: 
(objective of the study clearly described, study design 
clearly stated, participants representative of the popula-
tion from which they were recruited, participants accrued 
during the same time period, modest sample size, man-
agement of missing data, age, gender and other character-
istics explored/reported, e.g. were confounders reported, 
was detection method of HBV reported, were potential 
biases reported, was outcome clearly described?), the 
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assessment also included other items known to be asso-
ciated with study quality [10, 17]. Each study was issued 
with a unique number for identification purposes and 
the following descriptive information collected; author 
details, year of publication, region of Ghana, type of study 
population, mean age of subjects, number of subjects 
involved (sample size), setting (rural vs urban), gender of 
study participants and the HIV/HBV coinfection preva-
lence rate. Data were independently extracted by RO and 
AA and compared. Any disagreements or discrepancies 
were resolved by consensus-based discussions.
Data analysis
We analyzed the results by meta-analysis proportions 
performed with OpenMeta (analyst) software, an open-
source, cross-platform software for advanced meta-
analysis [18] and StatsDirect statistical software (Version 
3.0.0, StatsDirect Ltd, Cheshire UK) [19]. Individual study 
proportions were assessed at 95  % confidence interval 
(CI) as well as the pooled effect. Between-study hetero-
geneity was assessed by the Quoran (Q) statistic test and 
the I2 statistic, which represents the percentage of total 
variation across studies, attributable to heterogeneity 
rather than to chance [20]. A p value of <0.1 was consid-
ered to be statistically significant for the Q-statistics test 
and an I2 >50 % was deemed to represent meaningful het-
erogeneity in which case the random effect model (Der-
Simonian-Laird) was adopted over fixed effect model in 
the summary of pooled analysis [20]. To assess the publi-
cation bias and small-study bias, a funnel plot of the data 
was applied. In addition, Egger and Begg’s tests were used 
to detect publication bias [21, 22]. A leave-one-out sen-
sitivity analysis was performed by iteratively removing 
one study at a time to confirm how each individual study 
affects the overall estimate of the rest of the studies [23]. 
For all computations except the between-study heteroge-
neity testing, statistical significance was set at p < 0.05.
Ethical approval
An ethical approval was not required for this study as it 
was based on data/information retrieved from published 
studies already available in the public domain.
Results
Overview of studies
Figure 1 outlines the articles’ search and retrieval steps. A 
total of 1220 citations were identified through electronic 
search and other sources. After the exclusion of dupli-
cates and irrelevant studies based on titles and abstracts, 
fourteen (14) articles were retrieved for detailed full-text 
analysis. Out of the 14 studies, twelve (12) met the inclu-
sion criteria for addition to the review [24–35]. The 12 
studies (Table  1) reported HBV coinfection prevalence 
rate in a total HIV-positive patient’s population size of 
8162. The sample size (number of HIV infected patients) 
across the 12 studies ranged from 12 to 3108. The studies 
were conducted across seven (7) of the ten (10) regions of 
Ghana. The regional breakdown of the studies were as fol-
lows; Ashanti (n = 3), Brong-Ahafo (1), Eastern (2), West-
ern (1), Northern (1), Greater Accra (3) and one study that 
involved multiple regions (Greater Accra, Ashanti, Eastern 
and Volta). Fifty-eight percent (7/12) of studies were con-
ducted among HIV patients visiting HIV clinics whereas 
17 % (2/12) were conducted among blood donors with same 
proportion (17 %, 2/12) of studies being carried out in preg-
nant women attending antenatal clinics. The oldest identi-
fied study was published in 1999 [24] and the most recent 
study identified was published in 2016 [35]. Ninety-two per-
cent (92 %) of studies were published within the last decade 
(2006–2016) and as much as seventy-five percent (75 %) of 
studies were published within the last five (5) years (2011–
2016). In studies that presented gender distribution, female 
participants were of higher proportion. The overall quality 
grading identified 59, 33 and 8 % of studies included in the 
review to be of high, moderate and low quality respectively. 
Meta‑analysis findings
A total of 8162 HIV infected patients were involved in the 
12 studies included in this review. The pooled HIV/HBV 
coinfection prevalence rate (Fig. 2) across the twelve (12) 
studies published between 1999 and 2016 in Ghana was 
13.6  % (95  % CI 10.3–16.8  %; p  <  0.001). Heterogeneity 
Chi squared (Q) was 161.7 (degree of freedom, d.f = 11), 
and I2 was determined as 93.2 % for the degree of incon-
sistency. The estimate of between-study variance Tau-
squared was 0.002.
A funnel plot of HBV/HIV coinfection prevalence rates 
did not reveal a completely symmetrical display of the 
prevalence rates reported by the various studies (Fig. 3). 
However, we did not deduce any strong evidence of 
publication bias as revealed by Egger’s (p = 0.1604) and 
Begg’s (p = 0.7373) tests.
To assess the robustness of the HIV/HBV coinfection 
prevalence results, we performed a leave-one-out sensitiv-
ity analysis by iteratively removing one study at a time while 
recalculating the coinfection prevalence rate. The weight of 
the individual summaries on the pooled effect showed that 
the prevalence estimate was dominated by Walana et  al. 
[31], Archampong et al. [35] and Kye-Duodu [29] (Fig. 4).
Discussion
The overall prevalence of HIV/HBV coinfection was 
determined to be high at 13.6  %, suggesting that about 
one in seven HIV positive patients in Ghana may be con-
currently suffering from chronic HBV infection. Even for 
the analysis presented in this review, it is likely that the 
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pooled estimates may be modest considering that major-
ity of studies failed to account for the presence of occult 
HBV which is described as the occurrence of replication-
competent HBV DNA in the liver with undetectable hep-
atitis B surface antigen (HBsAg) [36]. This often occurs 
after progressive disappearance of HBsAg in the years fol-
lowing infection and persisting in low-level carriers [37].
A recent systematic review estimated the prevalence 
of chronic HBV infection among Ghanaians to be 12.3 % 
[16], suggesting that HIV patients in Ghana tend to 
develop chronic HBV infection more so than the general 
population. Similar trends have been observed across 
many parts of the world and there are theoretical expla-
nations to account for this, including the shared trans-
mission routes of both diseases and the limited immune 
system capacity to resolve acute HBV infections in HIV 
patients [2, 3].
In Ghana, HBV testing and monitoring in HIV patients is 
not routine. As a result, although, the World Health Organ-
ization (WHO) recommends that ART be initiated in HIV 
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Fig. 1 A schematic flow of studies’ search and retrieval processes
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co-infected patients irrespective of CD4 count [11], this is 
practically not being followed. The consequences has been 
that several HIV/HBV co-infected patients do not benefit 
from early treatment programs since current practices only 
takes into consideration the patient’s CD4 count level for 
the purpose of initiating ART [11]. The overall high preva-
lence of HBV in HIV patients as determined in this review 
necessitates the need for a national policy to offer HBV 
screening as part of the comprehensive care for all HIV 
positive persons as done in advanced countries like US and 
Canada where coinfection rates are even lower [2]. HIV 
patients who are detected to be HBV-seronegative, should 
be offered vaccination which ideally should be covered 
under the country’s National Health Insurance Scheme 
(NHIS) to ensure that most patients can benefit.
HIV/HBV coinfection increases the morbidity and mor-
tality beyond those individually caused by both infections 
and this is likely to impose significant constraints on 
the already stretched health resources in Ghana. In HIV 
patients, the concurrent infection with HBV has been rec-
ognized to lead to increased tendency for the occurrence 
of AIDS-related and non-AIDS-related clinical outcomes, 
such as end-stage liver diseases including cirrhosis and 
HCC [38, 39]. Already, HBV is a significant contribu-
tor to the burden of HCC in Ghana. In a study by Blank-
son et al., at least two in five cirrhotic patients in Ghana 
were identified to be suffering from chronic HBV infec-
tion [40]. High rates of coinfection are likely to exacerbate 
these statistics.
The treatment for chronic HBV in Ghana is estimated to 
cost about $100–150 a month or same weekly to take an 
injection for 48 weeks as a way of managing the condition 
[16]. These costs are likely to be beyond the affordability 
of most HIV patients in Ghana neither will it be sustain-
able to finance through any public health funding scheme. 
Primary prevention through measures such as vaccination 
therefore seems the most reasonable approach in these 
circumstances. Such measures must be accompanied by 
widespread education campaigns regarding the transmis-
sion and infection dynamics of these viral pathogens. In 
Ghana, knowledge and awareness on HBV is documented 
to be low [41, 42]. In a recent assessment of 200 certified 
barbershops within the Kumasi metropolis in the Ashanti 
region, less than 10 % knew the route of transmission of 
HBV [41]. Additionally, the broader societal misconcep-
tions regarding HBV such as the conceptualization of the 
disease as a purely sexually transmitted infection should 
be addressed through effective public education [16].
The high HIV/HBV coinfection rate should be given 
the needed attention and addressed to avert undue 
Fig. 2 Forest plot of reported HIV/HBV coinfection prevalence rates across studies conducted in Ghana between 1999 and 2016
Fig. 3 Bias assessment plot of reported HIV/HBV coinfection preva‑
lence rates across studies published in Ghana between 1999 and 
2016
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consequences. The economic and health-related (arising 
from ARTs, management of opportunistic infections etc.) 
cost of HIV alone is enormous and likely to be exacer-
bated by concurrent infections with HBV. Moreover, as 
has been widely observed, peak ages for AIDS cases in 
Ghana are 25–34  years for females and 30–39  years for 
males [43]. These age groups represent some of the most 
productive years and therefore increased morbidity and 
mortality arising from coinfection with HBV is likely 
to result in significant loss of man power and thereby 
impact on economic development in the country.
There are some limitations to this study. The accuracy of 
detection of active HBV infection depends on a number of 
factors such as the screening method employed [16]. Over 
the years, the sensitivity and specificity of HBV screening 
tools have improved and this could impact on the differ-
ence prevalence rates reported across studies published in 
different years. While all efforts were made to explore all 
resources, we retrieved only studies from seven of the 10 
regions of Ghana. The overall estimate may therefore not 
fully represent the national situation. However, it is worth 
mentioning that according to the Ghana AIDs Commis-
sion [44], over 80  % of HIV patients in Ghana, reside in 
these seven region and the overall estimate presented in this 
review may therefore not deviate significantly from a true 
national prevalence. Nevertheless, this does not eliminate 
the fact that only a large representative national epidemio-
logical study conducted at the same time in all regions can 
give a more reliable and accurate overall prevalence of HBV/
HIV coinfection in Ghana [10]. This will also help to address 
the high heterogeneity as observed in this review.
Estimates of HIV/HBV coinfection prevalence rate in 
Ghana are currently lacking and as such this study opens 
new doors towards building a stronger evidence regard-
ing HIV/HBV burden in Ghana. The HIV/HBV coin-
fection prevalence reported in this review should guide 
policy makers and health personnel towards improv-
ing the care of HIV/AIDS and HIV/HVB co-infected 
individuals.
Conclusion
The prevalence of HIV/HBV coinfection in Ghana is 
high. Preventive interventions and strategic policy 
directions including systematic screening of all newly 
diagnosed HIV cases for coinfection will be needed, so 
as to improve management strategies for HBV infection 
and antiretroviral therapy (ART) implementation.
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